Seeking Alpha

KarinCA

 
View as an RSS Feed
View KarinCA's Comments BY TICKER:
Latest  |  Highest rated
  • Update: Tekmira Clinical Hold Lifted [View article]
    Upbeat... It didn't take the FDA long at all to change the hold to a partial one. The hold was put on fairly recently and removed much earlier than most had anticipated.

    Politics and cultural differences have been the root of the problem. Many on the ground in Africa feared giving the populace untested treatments due to heavy distrust of the aid workers. Now, that the disease is affecting people in heavily populated areas the local governments are finally becoming more proactive in trying to get outside help which includes untested therapies. They are now at a desperate point and begging for any therapies that may work. That opened the door for the FDA to become a bit more lenient here. Politicians are pushing them now.

    The perceived importance or lack thereof of the affected population had nothing to do with these decisions. The affected population is simply very distrusting of outsiders coming in with treatments. Especially, seeing them outfitted in protective gear. It has to be very frightening for these people.

    I'm just hoping TKM-Ebola works in people as well as it does in animals.
    Aug 8 06:51 PM | Likes Like |Link to Comment
  • Update: Tekmira Clinical Hold Lifted [View article]
    Ah, I see you clarify the partial hold further in.... I'd only read the summary when I made comment about it only being a partial hold.

    It's up on huge volume thus far... be interesting to see how the day ends. Glad to be holding here. ;)
    Aug 8 01:03 PM | Likes Like |Link to Comment
  • Update: Tekmira Clinical Hold Lifted [View article]
    TKM-Ebola is a therapeutic agent that is 100% curative in already infected primates. It's not a vaccine. You can see how the company refers to it in the following pr.

    http://bit.ly/1kOEqfE
    Aug 8 12:57 PM | Likes Like |Link to Comment
  • Update: Tekmira Clinical Hold Lifted [View article]
    The hold hasn't been lifted. It has been reduced to a partial hold.

    FDA Modifies Tekmira's TKM-Ebola Clinical Hold to Partial Hold
    http://on.mktw.net/1kO...
    Aug 8 12:46 PM | Likes Like |Link to Comment
  • International Stem Cell Solves Immune Rejection Issue For Significant Segment Of Population [View article]
    International Stem Cell Corporation Secures Approval for Core Technology Patents in European Union

    http://yhoo.it/1A2P4DQ
    Jul 22 04:03 PM | 1 Like Like |Link to Comment
  • International Stem Cell Solves Immune Rejection Issue For Significant Segment Of Population [View article]
    CJEU Court Agrees with ISCO and UK Court. Finds Parthenote?s not Human Embryos. This opens the way for EU patents to be filed.

    The Advocate General delivered his opinion this morning, agreeing with the UK Court and ISCO that parthenotes, because they cannot become humans, should not be considered part of the definition of a human embryo.

    http://bit.ly/1pe6jLc;jsessionid=9ea7d0f130...

    "V - Conclusion

    80. In the light of the foregoing, I suggest that the Court should answer the question referred by the High Court of Justice, Chancery Division (Patents Court) as follows:

    Unfertilised human ova whose division and further development have been stimulated by parthenogenesis are not included in the term 'human embryos' in Article 6(2)(c) of Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions as long as they are not capable of developing into a human being and have not been genetically manipulated to acquire such a capacity."
    Jul 17 10:32 AM | 1 Like Like |Link to Comment
  • International Stem Cell Solves Immune Rejection Issue For Significant Segment Of Population [View article]
    ISCO - International Stem Cell Corporation Signs Agreement Including Certain Terms for a Definitive License Agreement With Rohto Pharmaceutical Co., Ltd. of Japan

    http://bit.ly/1jbaZDu
    Jul 8 08:49 AM | 2 Likes Like |Link to Comment
  • DSMB gives thumbs up for continuation of brilacidin trial [View news story]
    glenkaiser06... The company has a healthy pipeline with three drugs in clinical trials. The only reason we hear so much about Briliacidin is because we'll get trial results from it first.

    http://1.usa.gov/1jHYE5I
    Jul 7 06:11 PM | Likes Like |Link to Comment
  • DSMB gives thumbs up for continuation of brilacidin trial [View news story]
    ellaruth.... Cellceutix purchased most of the PolyMedix assets, not the company itself. The assets primarily consisted of intellectual property that includes a great pipeline. There is no PolyMedix to spin off as an ipo.
    Jul 7 06:08 PM | Likes Like |Link to Comment
  • International Stem Cell Solves Immune Rejection Issue For Significant Segment Of Population [View article]
    The CEO has controlling interest in X-Master, Inc. and that gives him enough shares that he can basically do what he wants. http://1.usa.gov/1sVEA85

    I'm still in, but, had trimmed my position by quite a bit. I bought back in a bit heavier this morning, but, only as a trading position. I want to be in when the IND is filed, but, like you, I don't like some of the things management has done recently.

    Good luck to you and everyone else.
    Jul 1 08:46 PM | 1 Like Like |Link to Comment
  • International Stem Cell Solves Immune Rejection Issue For Significant Segment Of Population [View article]
    Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer and Dr. Ruslan Semechkin, the Company’s Chief Scientific Officer and a director purchased common stock at .10 cents per share on 6.26.14. This was reported in an 8k filed by the company on 7.1.14

    http://1.usa.gov/1rbpyJD

    The individuals reported this on Form 4’s as follows:

    ~~~~~~~~~

    CEO Andrey Semechkin made a direct purchase of 4,800,000 shares on 6.26.14 at .10 cents per share according to the following Form 4:

    http://1.usa.gov/1rbpAkR

    ~~~~~~~~~~

    Chief Scientific Officer Ruslan Semechkin made a direct purchase of 700,000 shares on 6.26.14 at .10 cents per share according to the following Form 4:

    http://1.usa.gov/1rbpAB7
    Jul 1 07:24 AM | Likes Like |Link to Comment
  • International Stem Cell Solves Immune Rejection Issue For Significant Segment Of Population [View article]
    It looks like the market didn’t like the warrant exchange for common shares earlier this month. Some of the key insiders benefited. Those same insiders have been supporting the company through their own purchases, but, the perception is poor. Especially, since the company hasn't explained the rational for this. Is it a logical move to get the warrant liability off the books and prep for further financing down the road? Or, is it a simple share grab by insiders? One has to wonder.

    See the following filing from 6.12.14: http://1.usa.gov/1yH1PDo
    Jun 25 03:18 PM | Likes Like |Link to Comment
  • An Early Valuation Of Neuralstem's NSI566 [View article]
    Larry O... You ask a good question. But, Genervon's study results haven't been posted yet. I'm curious how their results will compare to both CUR and BCLI

    http://1.usa.gov/1lz7shd

    The clinical trials site was last updated February 2014, but, results are due this month.

    Here is Genervon's most recent pr on it from April 2014: http://bit.ly/1lz7shf

    I wonder if they've come up with a partner yet?
    Jun 14 04:16 PM | Likes Like |Link to Comment
  • Advanced Cell Technology's Intellectual Property Takes A Hit [View article]
    Esekla... ACTC's patent position is already weak.

    A major issue is how much of ACTC’s intellectual property has already been licensed away in an effort to survive. The following doesn’t cover all the agreements, but, they should give you a better idea of what shareholders are actually getting when considering investing in ACTC. Odds are high that most ACTC investors don’t realize how much has been licensed away at poor terms overall.

    ISCO’s Lifeline subsidiary entered a licensing agreement with ACTC in 2004 which was amended in 2005. Lifeline acquired know how in addition to the license. Lifeline also entered into an agreement with BTX and their affiliate Embryome Sciences for product production and distribution of embryonic progenitor cells or lines and products derived from them.

    August 25, 2005
    http://1.usa.gov/R55glB

    June 25, 2008
    http://bit.ly/R55glD

    http://bit.ly/R55f15

    ACTC entered exclusive license and partnering agreement with Embryome Sciences, Inc, an affiliate of BTX in 2008.

    July 2008
    http://1.usa.gov/R55gBT

    BTX has sublicensed the rights to the ACTC know how, patent rights and stem lines to other researchers. BTX will benefit from the royalties, not ACTC.

    ACTC entered into an exclusive license agreement with CHA Biotech Co., LTD, a Korean company in 2009.

    March 30, 2009
    http://1.usa.gov/R55gBV

    This agreement covered the retinal pigment epithelial technology along with ACTC’s single cell biopsy technique. There is much more to the story concerning the CHA agreements following this one, but, time doesn’t permit me to post it all. Suffice it to say that CHA got the better end of the deals.

    Good luck in your investing.
    Apr 30 10:54 PM | Likes Like |Link to Comment
  • Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price [View article]
    Alex_77 ...
    ACTC is fully reporting: http://1.usa.gov/R55f13

    The larger issue is how much of ACTC’s intellectual property has been licensed away in an effort to survive. The following doesn’t cover all the agreements, but, they should give you a better idea of what you are actually getting when considering investing in ACTC. Odds are high that most ACTC investors don’t realize how much has been licensed away at poor terms overall.

    ISCO’s Lifeline subsidiary entered a licensing agreement with ACTC in 2004 which was amended in 2005. Lifeline acquired know how in addition to the license. Lifeline also entered into an agreement with BTX and their affiliate Embryome Sciences for product production and distribution of embryonic progenitor cells or lines and products derived from them.

    August 25, 2005
    http://1.usa.gov/R55glB

    June 25, 2008
    http://bit.ly/R55glD

    http://bit.ly/R55f15

    ACTC entered exclusive license and partnering agreement with Embryome Sciences, Inc, an affiliate of BTX in 2008.

    July 2008
    http://1.usa.gov/R55gBT

    BTX has sublicensed the rights to the ACTC know how, patent rights and stem lines to other researchers. BTX will benefit from the royalties, not ACTC.

    ACTC entered into an exclusive license agreement with CHA Biotech Co., LTD, a Korean company in 2009.

    March 30, 2009
    http://1.usa.gov/R55gBV

    This agreement covered the retinal pigment epithelial technology along with ACTC’s single cell biopsy technique. There is much more to the story concerning the CHA agreements following this one, but, time doesn’t permit me to post it all. Suffice it to say that CHA got the better end of the deals.

    Good luck in your investing.
    Apr 30 09:25 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
242 Comments
332 Likes